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1. INTRODUCTION 
Heparin exerts its anticoagulant action by accel- 
erating the rate at which the plasma protease in- 
hibitor antithrombin inactivates coagulation prote- 
ases [ 11. The accelerating effect depends on the tight 
binding (K - 10’ M -‘) of heparin molecules to 
antithrombin, which results in a conformational 
change of the inhibitor 12-51. Only - 1/3rd of the 
molecules in heparin preparations bind with high 
affinity to antithrombin [6-81. These molecules 
contain a specific, antithrombin-binding, pentasac- 
charide sequence that includes a unique, 3-O-sul- 
phated glucosamine residue 19, lo]. Oligosaccharides 
(octasaccharides and larger) containing this anti- 
thrombin-binding sequence have been isolated by 
affinity chromatography following partial depoly- 
merization of the polysaccharide with nitrous acid 
[ 10,l I]. The ability of these oligosaccharides to po- 
tentiate the inhibition of individual coagulation en- 
zymes varies with molecular size; species composed 
of < 16 sugar units are essentially unable to accel- 
erate the inhibition of thrombin by antithrombin, 
but greatly enhance the rate of inhibition of factor 
X, [ 12,131. This finding suggests that the accelera- 
tion of the inactivation of thrombin, but not that of 
factor X,, involves a direct interaction between 
heparin and the enzyme [ 12- 151. 
Here, we present a method for covalently 
attaching a high-affinity heparin oligosaccharide 
to antithrombin and show that this binding results in 
similar reactivity of the inhibitor against factor X, 
as that caused by only non-covalently bound oligo- 
saccharide. Therefore, we conclude that the oligo- 
saccharide is covalently bound at the heparin 
binding site of antithrombin and permanently acti- 
vates the inhibitor. 
2. MATERIALS AND METHODS 
Bovine antithrombin was isolated by affinity 
chromatography on heparin-Sepharose 1161. Con- 
centrations of the protein were determined by ab- 
sorbance measurements at 280 nm with the use of 
an absorption coefficient of 0.67 1. g -’ . cm -’ [ 171. 
An M, = 56 000 [ 171 was used for calculation of 
molar ratios. 
Heparin oligosaccharides were produced by par- 
tial deaminative cleavage of commercial heparin 
(Kabi-Vitrum, Stockholm), with nitrous acid, es- 
sentially as in [lo]. Oligosaccharides with high aflin- 
ity for antithrombin were isolated from this pre- 
paration by affinity chromatography on the 
matrix-linked protein [7,10] and were used with- 
out further size fractionation. Alternatively, a tetra- 
decasaccharide (M, - 3700) was isolated from a 
similar preparation by gel chromatography on 
Sephadex G-50 [ 181. 
Purified commercial heparin was coupled to 
CNBr-activated agarose [19] with a resulting 
heparin content of 2.2 mg/ml wet gel. 
Heparin concentrations were determined by the 
carbazole method [20]. In analyses of the polysac- 
charide in the presence of antithrombin, the absorb- 
ance given by the same amount of the protein alone 
was subtracted. 
Antithrombin activity against thrombin or factor 
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X, was meaured by spectrophotometric assays with 
chromogenic oligopeptide substrates 121,221. 
3. RESULTS AND DISCUSSION 
Reaction of a 2-amino-2-dkoxy-D-glucopyrano- 
syl residue with nitrous acid results in the formation 
of a 2,5-anhydro-D-mannose unit, the aglycon 
being released [23]. Minor amounts of 2-de- 
oxy-2-C-(formyl)-D-arabino-pentofuranoside are 
also formed [24]. Treatment of heparin with 
nitrous acid thus leads to the formation of frag- 
ments having 2,5-D-anhydromannose residues, 
with reactive aldehydo functions, at their reducing 
terminals [ 10,251. Oligosaccharides obtained in this 
manner, with high affinity for antithrombin, were 
covalently attached to the protein by a procedure 
based on the formation of a labile Schiff base be- 
tween the anhydromannose residue of an oligosac- 
charide non-covalently bound to the inhibitor and 
the amino group of any neighbouring lysine residue 
of the protein. Such a Schiff base can be reduced to 
a secondary amine with NaCNBH3 in aqueous 
solution at neutral pH, which results in formation of 
a stable covalent bond [26]. The high-affinity oligo- 
saccharides, either unfractionated with regard to 
molecular size (3.8 mg) or isolated tetradecasac- 
charide (3.5 mg), were mixed with antithrombin 
(20-25 mg) in 10 ml 0.1 M sodium phosphate (pH 
7.0). The amount of tetradecasaccharide corres- 
ponds to a molar ratio relative to the protein of 
-2.7; 15 mg NaCNBHJ was added, and the reac- 
tion was allowed to proceed at room temparature 
for 24 h. Antithrombin (free and conjugated) was 
then separated from unreacted oligosaccharides 
and excess reagent on a column of Sephadex G- 100 
(2.5 X 95 cm) in 1.5 M NaCl, 0.02 M sodium 
phosphate (pH 7.0). The high salt concentration 
was used to dissociate any non-covalently bound 
oligosaccharide from the protein. 
After dialysis, antithrombin containing covalent- 
ly bound oligosaccharide was separated from resid- 
ual unreacted protein by affinity chromatography 
on heparin-agarose (lig.1). The rationale of this 
experiment was that the bound oligosaccharide 
would be expected to block the heparin binding site 
of the inhibitor and thereby prevent the antithrom- 
bin-oligosaccharide conjugate from binding to the 
matrix-linked heparin. The chromatogram shown is 
that obtained with antithrombin reacted with the 
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Fig. 1. Separation of antithrombin containing covalently 
bound, high affinity heparin oligosaccharide from un- 
reacted antithrombin by affinity chromatography on 
heparin-agarose. An amount of 18 mg antithrombin, 
reacted with unfractionated, high-affinity oligosacchar- 
ides and separated from excess reagents on Sephadex 
G-100, was applied in 6 ml at 30 ml/h to a 2.6 x 6 cm 
column of heparin-agarose in 0.05 M NaCl, 0.05 M Tris- 
HCl (pH 7.5) after dialysis against this buffer. Elution 
was performed at 60 ml/h with a linear gradient (total 
vol. 200 ml) to 1.5 M NaCl in the same Tris buffer. The 
arrow marks the start of the gradient: (-) A2se; (. . .) 
(NaCl] measured by conductimetry. The numbers give 
the amount of protein in each fraction in % of the total 
amount recovered, which was 88% of that applied to the 
column. 
unfractionated high-affinity oligosaccharide pre- 
paration. As anticipated, a large peak (40% of the 
total protein recovered) without affinity for the im- 
mobilised heparin (fraction I) was obtained. This 
peak was found to contain heparin and to have 
considerable activity against factor X, without 
heparin added, as expected for the conjugate. The 
small peak with low affinity for the matrix-linked 
heparin (fraction II) also contained some heparin 
and had activity; however, due to the small amount 
of material in this peak it was not investigated fur- 
ther. Fraction III eluted from the immobilised 
heparin at the same ionic strength as untreated 
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antithrombin and was found to contain no heparin 
by carbazole analysis. Moreover, this fraction 
showed the same low activity against thrombin or 
factor X, in the absence of added heparin as un- 
treated antithrombin and also the same increase 
in activity against both enzymes after addition of 
the polysaccharide. It was therefore concluded that 
fraction III consisted of antithrombin that had not 
reacted with any oligosaccharide. 
Similar results as these were obtained for the 
isolated tetradecasaccharide, reacted with the pro- 
tein under the same conditions. Reducing the oligo- 
saccharide/protein ratio to -50% in an experi- 
ment performed only with unfractionated oligosac- 
charides resulted in a proportional decrease in the 
yield of fraction I. Treatment with NaCNBH3 only 
did not affect the elution behaviour of antithrombin 
on heparin-agarose, nor the activity of the protein. 
Before final analyses, the protein in fraction I was 
separated from possibly remaining unconjugated 
oligosaccharide, or from heparin that might have 
leaked from the heparin-agarose, by gel chroma- 
tography on a column of Sephadex G-200 (1.6 x 90 
cm) in 1.5 M NaCl, 0.02 M sodium phosphate (pH 
7.0). The amount of heparin associated with the 
protein was then analysed by the carbazole method, 
and the activity of the protein against factor X, in 
the absence of added heparin was determined 
(table 1). The conjugates isolated after reaction of 
antithrombin with either the unfractionated oligo- 
saccharide preparation or with the tetradecasac- 
charide contained -5% heparin, on a weight 
basis. This value corresponds to a molar ratio of 
tetradecasaccharide/antithrombin that is not 
Table I 
Heparin oligosaccharide content and anti-factor X, activity of covalent oligosaccharide-antithrom- 
bin complexes 
High-affinity oligosaccharide Saccharide/ Activitya (W) 
bound to antithrombin antithrombin Ionic strength Ionic strength + PolybreneC 
weight molar = 0.15b = l.OC 
Unfractionated 0.05 
Tetradecasaccharide 0.05 
Controld 0.5 
Controld 0.1 
0.7 
98 87 76 
98 85 80 
100 0 n.d 
100 n.d. 0 
n.d., not determined 
a Expressed as the amount of factor X, inactivated by the sample (without heparin added) in % of the 
amount of enzyme inactivated by the ‘controls (assayed at ionic strength = 0.15 and without 
polybrene) 
b In the standard assay, 50 ~1 sample or untreated antithrombin (15-18 mg/l in 0.05 M Tris-HCl 
(pH 8.2) ionic strength = 0.15) was incubated at 37°C for 7 min with 50 pl buffer or oligosaccharide 
solution in buffer; 50 ~1 factor Xa (13 ICTH units/ml in the Tris-HCl buffer) was added, and the 
incubation was continued for 20 s. A 100 ~1 portion was then transferred to a photometric cuvette at 
37°C containing 400 ~1 1 mM Bz-Ile-Glu-Gly-Arg-pNA (S-2222; AB Kabi, Stockholm) in the 
Tris-HCI buffer. The rate of release ofp-nitroaniline from the substrate was monitored at 405 nm. 
The proportions of antithrombin and factor X, were such that nearly all the enzyme was inactivated 
in the presence of an excess of heparin. The inactivation of factor X, by antithrombin alone was 
negligible 
c The reactions between the samples or controls and factor X, were performed at ionic strength = 1 .O 
or in the presence of 3.5 mg/l polybrene (at ionic strength = 0.15) 
d The controls were untreated antithrombin in the presence of noncovalently bound, Mr-unfraction- 
ated, high-affinity oligosaccharide at the weight ratios given. The two controls gave the same 
anti-factor X, activity at ionic strength = 0.15 in the absence of polybrene. Substitution of 
comparable amounts (on a weight basis) of high-affinity heparin for oligosaccharide also gave no 
activity at ionic strength = 1 .O or in the presence of polybrene 
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experimentally distinguishable from one, in view 
of the errors involved in the heparin determin- 
ation (table 1). Moreover, the two putative anti- 
thrombin-oligosaccharide conjugates had about 
the same activity against factor X, at physiolog- 
ical ionic strength and without heparin added as 
untreated antithrombin in the presence of an excess 
of oligosaccharide (table 1). 
To further ensure that the activity of the samples 
was not due to contaminating, non-covalently 
bound heparin, we also assayed the activity at an 
ionic strength of 1.0 or in the presence of the hepa- 
rin-binding polycation polybrene (table 1). Under 
these conditions, untreated antithrombin in the 
presence of added oligosaccharide or heparin had 
no detectable activity. In contrast, the anti-factor X, 
activities of the 2 conjugate samples were only 
moderately decreased with either assay modification. 
This decrease may indicate either the presence of 
small amounts of non-covalently bound heparin or 
oligosaccharide in the two samples, or, alternative- 
ly, that both a high salt concentration and the pres- 
ence of polybrene to some extent influence the 
interaction also between covalently bound oligo- 
saccharide and antithrombin. However, the analy- 
ses strongly support the conclusion that the major 
part of the heparin is covalently linked to the in- 
hibitor, 
Together, these results show that high-affinity 
heparin oligosaccharides can be covalently attached 
to antithrombin by the method used and that these 
covalently bound oligosaccharides activate the in- 
hibitor. The oligosaccharides therefore must be 
bound at the heparin binding site of the protein. 
Most likely, the covalent linkage is established 
while the oligosaccharides are reversibly associated 
with this site, and the noncovalent interactions are 
preserved also after formation of the covalent bond. 
Since the covalent binding presumably occurs be- 
tween the reducing terminal of the oligosaccharide 
and available lysine residues at or near the heparin 
binding site of the protein, the efficiency of the 
coupling should depend on the length of the oligo- 
saccharide. Apparently a tetradecasaccharide satis- 
fies the requirements for covalent binding; how- 
ever, more detailed studies of this problem are in 
progress with the use of radioactively labelled 
oligosaccharides of various lengths. Determination 
of the site(s) of covalent attachment in the protein 
sequence should contribute to the localization of 
amino-acid residues involved in the heparin 
binding state. 
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